Most Read Articles
Naomi Rodrig, 15 Jun 2016
An interim analysis from the multinational phase III CASTOR trial, presented recently at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that adding daratumumab to the standard two-drug regimen of bortezomib and dexamethasone markedly improved outcomes of patients with recurrent or refractory multiple myeloma.
Saras Ramiya, 14 Nov 2017
Accord Healthcare launches Accord Bortezomib® (bortezomib 3.5 mg per vial) for the treatment of patients with multiple myeloma and mantle cell lymphoma in Malaysia.
Su Ping Chuah, 01 Aug 2014

New immune therapies with new targets that can induce long-term remission in patients with advanced cutaneous T-cell lymphoma (CTCL) are needed, says an expert.

Radha Chitale, 01 Aug 2014

German experts came together to update guidelines on melanoma management and create consensus out of fragmented standards of care by experts across multiple fields.

Blood type tied to prognosis in hepatocellular carcinoma

13 Jul 2017

Blood type is associated with prognosis in Chinese hepatocellular carcinoma (HCC) patients, a new study reveals. Those with non-O blood types particularly have poorer overall survival (OS).

Over a median follow-up of 36 (25 to 75) months, 392 of the 691 HCC patients who received hepatectomy died. The 3- and 5-year survival rates were 52.9 and 38.7 percent, respectively.

Blood group was significantly associated with OS (p=0.001). The median OS for blood type O was 55 (95 percent CI, 42.69 to 67.31) months, type A 39 (32.20 to 45.80) months, type B 34 (26.58 to 41.42) months and type AB 34 (24.09 to 43.91) months.

Because the 1-, 3- and 5-year OS values for the blood type O group (88.2, 58.8 and 47.3 percent, respectively) were significantly higher than the type A/B/AB groups, which had comparable OS values (p=0.226), the study cohort was divided into O vs non-O blood type groups.

The resulting median OS for the blood type O group was 55 (42.69 to 67.30) months vs 36 (31.18 to 40.81) months for the non-O blood type group. Patients with blood type O had significantly better survival than those with non-O blood types (1-year OS, 88.2 vs 83.4 percent; 3-year OS, 58.5 vs 49.1 percent; 5-year OS, 47.3 vs 30.5 percent; p<0.001 for all).

Multivariate Cox regression analysis revealed that blood types A (hazard ratio [HR], 1.416; 95 percent CI, 1.101 to 1.820; p=0.007), B (HR, 1.736; 1.333 to 2.262; p<0.001) and AB (HR, 1.739; 1.210 to 2.499; p=0.006) were significant poor prognostic factors for HCC following hepatectomy.

The non-O blood type group (HR, 1.485; 1.204 to 1.830; p<0.001) had significantly worse OS compared with the O blood type group.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Naomi Rodrig, 15 Jun 2016
An interim analysis from the multinational phase III CASTOR trial, presented recently at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that adding daratumumab to the standard two-drug regimen of bortezomib and dexamethasone markedly improved outcomes of patients with recurrent or refractory multiple myeloma.
Saras Ramiya, 14 Nov 2017
Accord Healthcare launches Accord Bortezomib® (bortezomib 3.5 mg per vial) for the treatment of patients with multiple myeloma and mantle cell lymphoma in Malaysia.
Su Ping Chuah, 01 Aug 2014

New immune therapies with new targets that can induce long-term remission in patients with advanced cutaneous T-cell lymphoma (CTCL) are needed, says an expert.

Radha Chitale, 01 Aug 2014

German experts came together to update guidelines on melanoma management and create consensus out of fragmented standards of care by experts across multiple fields.